- Prevention in FocusCATIE asked two service providers about how their programs help to engage women at risk of syphilis in prenatal care and how they support syphilis prevention, testing and treatment.
- To achieve and maintain an undetectable viral load, people living with HIV need to take their HIV treatment as prescribed. In addition to taking HIV medications, regular medical visits are important…
- There has been a treatment revolution in hepatitis C: safe and highly effective direct-acting antiviral (DAA) treatment can now cure hepatitis C in as little as eight to 12 weeks. The availability of…
- WebinarThis webinar will present hepatitis C elimination strategies from the United States and Australia, two promising international models that can help inform our approaches to elimination efforts in…
- This fact sheet provides a snapshot of the hepatitis C epidemic in Canada.
- This CATIE statement summarizes the best available evidence on the effectiveness of PrEP to prevent HIV for people who use drugs. This statement was developed to help service providers in Canada…
- Syphilis has been on the rise in Canada, and around the world, for many years. Though it is preventable and curable syphilis outbreaks continue across the country. The following list of resources can…
- We offer instructor-led courses that combine online education with discussion forums and live training facilitated by knowledgeable CATIE educators. CATIE’s Hepatitis C Treatment course aims to…
- The CATIE statements summarize the best available evidence on the effectiveness of new approaches. These statements were developed to help service providers in Canada adapt their programs and…
- CATIE NewsA long-acting formulation of cabotegravir (Apretude) has been approved for HIV prevention. This drug has been highly effective in clinical trials at significantly reducing the risk of HIV. Apretude…
- CATIE NewsU.S. researchers surveyed a national sample of gbMSM about their PrEP preferences. The researchers reached more than 2,500 sexually active men via the Internet. 75% preferred to use long-acting PrEP…